Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients-Reference-Cited by-同舟云学术

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients

Published:2016-02-12 Issue:11 Volume:7 Page:12951-12961
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Trino Stefania¹,Iacobucci Ilaria²,Erriquez Daniela³,Laurenzana Ilaria¹,De Luca Luciana¹,Ferrari Anna²,Luserna Di Rorà Andrea Ghelli²,Papayannidis Cristina²,Derenzini Enrico²,Simonetti Giorgia²,Lonetti Annalisa⁴,Venturi Claudia²,Cattina Federica⁵,Ottaviani Emanuela²,Abbenante Maria Chiara²,Russo Domenico⁵,Perini Giovanni³,Musto Pellegrino⁶,Martinelli Giovanni²

Affiliation:

1. Laboratory of Pre-Clinical and Translational Research, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy

2. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. and A. Seràgnoli”, University of Bologna, Bologna, Italy

3. Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy

4. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

5. Chair of Hematology and BMT Unit, University of Brescia, Brescia, Italy

6. Scientific Direction, IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment;Frontiers in Pharmacology;2024-08-05

2. Ubiquitination Links DNA Damage and Repair Signaling to Cancer Metabolism;International Journal of Molecular Sciences;2023-05-08

3. miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia;Cancer Drug Resistance;2023

4. Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core;Journal of Enzyme Inhibition and Medicinal Chemistry;2022-08-31

5. p53 as a unique target of action of cisplatin in acute leukaemia cells;Journal of Cellular and Molecular Medicine;2022-08-09